CARLSBAD, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and producer of modern medical units that enhance spinal surgical procedure outcomes, at the moment introduced it has acquired 510(ok) clearance from the United States Food and Drug Administration (FDA) for the patented minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System. Additional particulars concerning the SiLO TFX MIS Sacroiliac Joint Fixation System can be disclosed by the Company in a extra fulsome press launch to be issued on October 6, 2022.
About Aurora Spine
Aurora Spine is concentrated on bringing new options to the spinal implant market by a sequence of modern, minimally invasive, regenerative spinal implant applied sciences. Additional data may be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Forward-Looking Statements
This information launch accommodates forward-looking data that includes substantial recognized and unknown dangers and uncertainties, most of that are past the management of Aurora Spine, together with, with out limitation, these listed underneath “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s closing prospectus (collectively, “forward-looking information”). Forward-looking data on this information launch consists of data regarding the proposed use and success of the corporate’s merchandise in surgical procedures. Aurora Spine cautions buyers of Aurora Spine’s securities about essential components that might trigger Aurora Spine’s precise outcomes to vary materially from these projected in any forward-looking statements included on this information launch. Any statements that categorical, or contain discussions as to, expectations, beliefs, plans, goals, assumptions or future occasions or efficiency should not historic info and could also be forward-looking and should contain estimates, assumptions and uncertainties which may trigger precise outcomes or outcomes to vary unilaterally from these expressed in such forward-looking statements. No assurance may be on condition that the expectations set out herein will show to be appropriate and, accordingly, potential buyers shouldn’t place undue reliance on these forward-looking statements. These statements converse solely as of the date of this press launch and Aurora Spine doesn’t assume any obligation to replace or revise them to mirror new occasions or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
Neither TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the TSX Venture Exchange) accepts duty for the adequacy or accuracy of this launch.
